DrugGen 2: A disease-aware language model for enhancing drug discovery
:::info Stub — Full Engineering Breakdown Coming This paper was featured on Hugging Face Daily Papers on 2026-07-09 with 19 upvotes. A full breakdown with production viability rating, implementation notes, and honest limitations is being written. Subscribe to AI Letters → :::
| Authors | Ali Motahharynia et al. |
| Year | 2026 |
| HF Upvotes | 19 |
| arXiv | 2607.08404 |
| Download | |
| HF Page | View on Hugging Face |
Abstract
Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavior and therapeutic outcomes. To address this gap, we introduce DrugGen-2, a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences. DrugGen-2 was developed by fine-tuning a pre-trained GPT-2 model on a curated dataset of approved drugs linked to their diseases and targets, using a two-step strategy of supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). This process was guided by reward functions optimizing for chemical validity, novelty, diversity, and high predicted binding affinity. When evaluated on five protein targets relevant to diabetic nephropathy, DrugGen-2 significantly outperformed baseline models (DrugGPT and DrugGen). It demonstrated a superior capacity to generate unique molecules, exhibited greater structural similarity to approved drugs, and achieved improved predicted binding affinities across all targets. Molecular docking analyses further supported these findings, identifying candidate ligands with strong binding potential, including compounds with predicted affinities (-9.917, -9.485, and -9.367) exceeding those of reference drugs such as enalapril for angiotensin-converting enzyme (-8.283). By integrating disease-specific context into molecular generation, DrugGen-2 advances AI-assisted drug discovery, offering a powerful tool for de novo design and drug repurposing that accounts for the complex interplay between diseases and molecular targets.
Engineering Breakdown
The Problem
Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavior and therapeutic outcomes.
The Approach
To address this gap, we introduce DrugGen-2, a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences.
Key Results
By integrating disease-specific context into molecular generation, DrugGen-2 advances AI-assisted drug discovery, offering a powerful tool for de novo design and drug repurposing that accounts for the complex interplay between diseases and molecular targets.
Research Areas
This paper contributes to the following areas of AI/ML engineering:
- Machine learning
- Deep learning
- Neural networks
- Model optimization
- AI systems
- Diseaseaware
:::tip Subscribe Get weekly breakdowns of papers like this in AI Letters - the newsletter for engineers building production AI systems. :::